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Introduction: Primary hypothyroidism is a well-known cause of poor linear growth in children. A rare finding with
profound or long-standing disease is anterior pituitary enlargement (pituitary pseudotumor). This case highlights
this uncommon finding, discusses clinical situations in which gradual dose escalation of levothyroxine may be
advisable and reviews adjuvant therapies that have been previously attempted to improve final height in the
setting of profound hypothyroidism.
Case presentation: We report the case of a 13-year-old Hispanic girl initially evaluated for poor linear growth and
delayed puberty, and found to have pituitary enlargement secondary to profound primary hypothyroidism.
Treatment with progressive doses of levothyroxine normalized her symptoms and led to complete resolution of her
pituitary findings, but she then rapidly progressed through puberty, achieving an adult height of only 142cm,
significantly below her calculated mid-parental height.
Conclusions: In cases of severe primary hypothyroidism with prolonged elevation of thyroid-stimulating hormone
and pituitary pseudotumor, gradual replacement of thyroid hormone with slowly escalating doses of levothyroxine
may be beneficial to prevent complications of therapy. Early recognition and treatment of hypothyroidism during
childhood is essential for normal growth, as final height is invariably compromised in children with prolonged
disease. Additional study is needed to determine the potential beneficial effects of gonadotropin-releasing
hormone agonist and recombinant human growth hormone treatment in this setting.
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Hypothyroidism is a well-known cause of poor linear
growth in children [1]. When hypothyroidism is prolonged
or severe, pituitary enlargement (pituitary pseudotumor)
can also be present [2]. This case highlights this uncom-
mon finding, discusses clinical situations in which grad-
ual dose escalation of levothyroxine may be advisable
and reviews adjuvant therapies that have been previ-
ously attempted to improve final height in the setting of
profound hypothyroidism.
Case presentation
A 13-year-old Hispanic girl presented to her primary
care physician for concerns of poor linear growth and* Correspondence: jordan.pinsker@us.army.mil
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distribution, and reproduction in any mediumdelayed puberty. She had only limited access to medical
care and had not been seen for a well-child visit for
many years. Upon initial evaluation, she was noted to
have had almost no linear growth since six years of age.
She complained of cold intolerance, dry skin, and was
easily fatigued with physical activity. On physical exam-
ination, her height and weight were at the 50th percentile
for a six-year-old (a height standard deviation score (SDS)
of −5). She had no breast development. She did not
have a goiter. Her skin was very dry and galactorrhea
was not present.
Extensive evaluation by a geneticist was undertaken
due to concern for a possible syndromic cause of her
poor growth. Her karyotype was normal. A brain magnetic
resonance imaging (MRI) scan was also performed, which
showed an enlarged pituitary gland, raising concern for a
possible pituitary macroadenoma (Figure 1). The patiententral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Enlarged pituitary gland at presentation. The enlarged pituitary gland measured 1.4cm in size and extended into the suprasellar cistern
(green arrows, coronal and sagittal views on T1-weighted post-gadolinium images).
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additional testing showed thyroid-stimulating hormone
(TSH) > 1000mU/L with an undetectable free T4 level,
suggesting the MRI finding was secondary to primary
hypothyroidism. Insulin-like growth factor 1 (IGF-1) was
low for her age, consistent with the well-established
phenomenon of decreased growth hormone secretion in
severe hypothyroidism. Her bone age was five years by the
standards of Greulich and Pyle at a chronological age of
13 years. Multiple biochemical abnormalities secondary to
hypothyroidism were also present (Table 1). Her serum
prolactin was not measured.
Treatment with levothyroxine was initiated at a rela-
tively low dose of 25μg/day (1.1μg/kg/day). Over time,
her dose of levothyroxine was gradually increased toTable 1 Laboratory values at initial presentation
TSH > 1000mU/L (normal 0.27-4.2)
FT4 < 0.5pmol/L (normal 13-23)
Karyotype 46, XX
IGF-1 11.2nmol/L (normal 25-84)
Cholesterol 11.9mmol/L (normal 1.3-5.2)
AST 78U/L (normal 14-50)
ALT 51U/L (normal 9-52)
Creatinine 65.4μmol/L (normal 53-88)
Hemoglobin 5.0mmol/L (normal 7.4-9.9)
Creatine kinase 1178U/L (normal 30-135)
Cortisol 333.8nmol/L (normal 166-386)
TSH, thyroid-stimulating hormone; FT4, free T4; IGF-1, insulin-like growth factor
1; AST, aspartate aminotransferase; ALT, alanine aminotransferase.100μg/day to achieve and maintain a normal TSH level.
Her linear growth velocity immediately improved to
12.9cm/year, and she rapidly progressed through puberty,
achieving menarche 18 months after starting treatment.
At 14 years and 10 months of age, her bone age was
12 years, indicating it had rapidly advanced. She achieved
a final adult height of only 142cm (−3 SDS), significantly
below her mid-parental height of 161.3cm (−0.4 SDS). A
follow-up pituitary MRI scan that was done 18 months
after treatment with levothyroxine was initiated showed
persistence of the enlarged sella with a normal positioned
and sized pituitary gland including normal stalk and pos-
terior bright spot (Figure 2), suggesting that the enlarged
pituitary seen at presentation was primarily caused by
thyrotroph hyperplasia that subsequently resolved.
Discussion
The presentation of primary hypothyroidism in children
is most often marked by poor linear growth [1], although
symptoms can be quite varied. In some cases, the ex-
tremely elevated thyrotropin-releasing hormone levels seen
in prolonged primary hypothyroidism can lead to the rare
finding of anterior pituitary enlargement (pseudotumor
of the pituitary gland) [2]. Sometimes there is hyperpla-
sia of not just thyrotrophs, but lactotrophs as well, caus-
ing hyperprolactinemia [3]. A prolactin level was not
measured in our patient but hyperprolactinemia could
explain in part her delayed puberty. In other cases, pitu-
itary enlargement thought to be related to precocious
puberty was actually thyrotroph hyperplasia [4,5]. In
these patients, it appears that either the weak intrinsic
follicle-stimulating hormone (FSH) activity of TSH can
Figure 2 Normal pituitary on follow-up magnetic resonance imaging scan. Eighteen months after treatment with levothyroxine was initiated
there was persistence of the enlarged sella (green arrows, coronal and sagittal views) with a normal positioned and sized pituitary gland including
normal stalk and posterior bright spot (T1-weighted post-gadolinium images).
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increased thyrotropin-releasing hormone causes an in-
creased FSH response [7]. The true isosexual precocious
puberty that results from prolonged hypothyroidism
(the van Wyk-Grumbach syndrome) is unique among
the causes of precocious puberty in that bone age is
often delayed at presentation.
Similar to our patient, some children with extremely ele-
vated TSH levels have been reported to present with pitu-
itary enlargement and growth failure without goiter [8].
Goiter is a well-established feature of chronic lymphocytic
thyroiditis and is often the first presenting sign of disease
in children. With prolonged lymphocytic infiltration,
the thyroid parenchyma may undergo fibrosis and goiter
may be absent [9]. Although we did not measure thyroid
peroxidase antibodies, we presume this patient had
long-standing autoimmune thyroiditis.
The importance of this case is highlighted in the
current controversy on treatment recommendations.
Treatment with levothyroxine results in normalization
of the size of the pituitary gland on subsequent imaging
studies. However, in patients with severe clinical signs
of hypothyroidism it may be advisable to gradually increase
the dose of levothyroxine over time, rather than starting at
the full anticipated replacement dose. There are a number
of reasons for this. First, patients with myxedema and peri-
cardial effusion secondary to hypothyroidism may not
tolerate becoming euthyroid rapidly, potentially worsen-
ing symptoms of heart failure. This is primarily an issue
for adults or children with other comorbidities, as recentreports suggest that otherwise healthy children generally
tolerate more rapid replacement of thyroid hormone [10].
Second, in severe, long-standing primary hypothyroidism,
it has been reported that pituitary and adrenal function
may be secondarily decreased, and adrenal insufficiency
may be precipitated by rapid replacement with thyroid
hormone [11]. In our patient this was not an issue, as her
cortisol level was normal prior to starting levothyroxine
therapy. Third, there have been case reports of adults
with thyrotroph hyperplasia due to primary hypothyroidism
who developed empty sella following replacement ther-
apy with levothyroxine, potentially indicating that rapid
shrinkage of the enlarged anterior pituitary may have
resulted in pituitary apoplexy [12]. Finally, pseudotumor
cerebri has been reported as a possible rare side effect
of treatment with levothyroxine.
As shown in this case, treatment with levothyroxine,
even with gradually escalated doses, often rapidly advances
osseous maturation, leading to premature physeal closure
[7]. When combined with precocious puberty or with
rapid osseous maturation following delayed puberty,
there can be a significant compromise of adult height.
Adjunctive therapy with gonadotropin-releasing hormone
(GnRH) agonists and recombinant human growth hor-
mone (rhGH) has been attempted to improve adult height
in patients with severe, primary hypothyroidism. Al-
though small studies and case reports have shown bene-
ficial results of combining GnRH agonist and rhGH
treatment with levothyroxine replacement [13,14], a
recent retrospective review suggested neither time to
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significantly affected height potential [15]. This sug-
gests that despite these treatments, skeletal maturation
rapidly advances. Additional study of these growth-
promoting therapies is needed in the setting of severe
primary hypothyroidism.
Conclusions
Pituitary enlargement (pseudotumor of the pituitary gland)
is a rare finding seen in prolonged and severe primary
hypothyroidism. Early diagnosis and treatment is essential
to preserve final height in children with severe primary
hypothyroidism, as late diagnosis almost invariably results
in decreased adult stature. Gradually increasing the dose
of levothyroxine over time has been tried, and may be
useful in children found to have associated pituitary
hyperplasia, cardiac pathology, or adrenal insufficiency,
but appears to be of limited utility with regard to height
outcomes. All families should be counseled on the likeli-
hood of attenuated final height. If severe growth retard-
ation is present, there may be a role for GnRH agonist
and/or rhGH treatment, but current efficacy data are
insufficient to routinely recommend the use of these
adjuvant treatments.
Consent
Written informed consent was obtained from the patient’s
legal guardian for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Abbreviations
FSH: Follicle-stimulating hormone; GnRH: Gonadotropin-releasing hormone;
IGF-1: Insulin-like growth factor 1; MRI: Magnetic resonance imaging;
rhGH: Recombinant human growth hormone; SDS: Standard deviation score;
TSH: Thyroid-stimulating hormone.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NSL provided direct patient care for this patient, and was a major
contributor in writing the manuscript. JEP was a major contributor in writing
the manuscript. Both authors read and approved the final manuscript.
Disclaimer
The views expressed in this manuscript are those of the author and do not
reflect the official policy or position of the Department of the Army,
Department of Defense, or the US Government.
Received: 27 November 2012 Accepted: 15 April 2013
Published: 31 May 2013
References
1. Rivkees SA, Bode HH, Crawford JD: Long-term growth in juvenile acquired
hypothyroidism: the failure to achieve normal adult stature. N Engl J Med
1988, 318:599–602.
2. Lee C, Salvatori R: Visual vignette. Thyrotroph cell hyperplasia. Endocr
Pract 2012, 18:429.
3. Alves C, Alves AC: Primary hypothyroidism in a child simulating a
prolactin-secreting adenoma. Childs Nerv Syst 2008, 24:1505–1508.4. Bhansali A, Jayaprakash P, Dutta P, Walia R, Ravikumar P: Precocious puberty
and a sellar mass. BMJ Case Rep 2009. doi:10.1136/bcr03.2009.1677.
5. Kocova M, Netkov S, Sukarova-Angelovska E: Pituitary pseudotumor with
unusual presentation reversed shortly after the introduction of thyroxine
replacement therapy. J Pediatr Endocrinol Metab 2001, 14:1665–1669.
6. Anasti JN, Flack MR, Froehlich J, Nelson LM, Nisula BC: A potential novel
mechanism for precocious puberty in juvenile hypothyroidism. J Clin
Endocrinol Metab 1995, 80:276–279.
7. Pinsker JE, Ferry RJ Jr: Pericardial effusion in the emergency department.
Endocrinologist 2004, 14:212–215.
8. Farley JD, Toth EL, Ryan EA: Primary hypothyroidism presenting as growth
delay and pituitary enlargement. Can J Neurol Sci 1988, 15:35–37.
9. Brent GA, Davies TF: Hypothyroidism and thyroiditis. In Williams Textbook
of Endocrinology. 12th edition. Edited by Melmed S, Polonsky KS, Larsen PR,
Kronenberg HM. Philadelphia: Saunders; 2011:406–439.
10. Tielens E, Visser TJ, Hennemann G, Berghout A: [Cardiovascular effects of
hypothyroidism]. Ned Tijdschr Geneeskd 2000, 144:703–706.
11. Kamilaris TC, DeBold CR, Pavlou SN, Island DP, Hoursanidis A, Orth DN:
Effect of altered thyroid hormone levels on hypothalamic-pituitary-
adrenal function. J Clin Endocrinol Metab 1987, 65:994–999.
12. Ahmed M, Banna M, Sakati N, Woodhouse N: Pituitary gland enlargement
in primary hypothyroidism: a report of 5 cases with follow-up data.
Horm Res 1989, 32:188–192.
13. Quintos JB, Salas M: Use of growth hormone and gonadotropin releasing
hormone agonist in addition to L-thyroxine to attain normal adult
height in two patients with severe Hashimoto's thyroiditis. J Pediatr
Endocrinol Metab 2005, 18:515–521.
14. Teng L, Bui H, Bachrach L, Lee P, Gagné N, Deal C, Wilson DM: Catch-up
growth in severe juvenile hypothyroidism: treatment with a GnRH
analog. J Pediatr Endocrinol Metab 2004, 17:345–354.
15. Nebesio TD, Wise MD, Perkins SM, Eugster EA: Does clinical management
impact height potential in children with severe acquired
hypothyroidism? J Pediatr Endocrinol Metab 2011, 24:893–896.
doi:10.1186/1752-1947-7-149
Cite this article as: Larson and Pinsker: Primary hypothyroidism with
growth failure and pituitary pseudotumor in a 13-year-old female: a
case report. Journal of Medical Case Reports 2013 7:149.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
